Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med. 2008 Oct 9;359(15):1577-89. Epub 2008 Sep 10.
PubMed PMID: 18784090.
研究デザイン： ランダム化比較試験 資金源： Supported for the first 5 years of post-trial monitoring bythe U.K. Medical Research Council, U.K. Department of Health,Diabetes UK, the British Heart Foundation, and the U.K. NationalInstitute for Health and for the final 5 years by Bristol-MyersSquibb, GlaxoSmithKline, Merck Serono, Novartis, Novo Nordiskand Pfizer. The original UKDPS interventional trial was supportedby the U.K. Medical Research Council, British Diabetic Association,U.K. Department of Health, U.S. National Eye Institute, U.S.National Institute of Diabetes and Digestive and Kidney Diseases,British Heart Foundation, Wellcome Trust, Charles Wolfson CharitableTrust, Clothworkers' Foundation, Health Promotion Research Trust,Alan and Babette Sainsbury Trust, Oxford University MedicalResearch Fund Committee, Novo Nordisk, Bayer, Bristol-MyersSquibb, Hoechst, Lilly, Lipha, and Farmitalia Carlo Erba, withconsumables or logistical support from Boehringer Mannheim,Becton Dickinson, Owen Mumford, Securicor, Kodak, Cortecs Diagnostics,Glaxo Wellcome, SmithKline Beecham, Pfizer, Zeneca, Pharmacia,Upjohn, and Roche. 利益相反： Dr. Holman reports receiving grant support from Asahi KaseiPharma, Bayer Healthcare, Bayer Schering Pharma, Bristol-MyersSquibb, GlaxoSmithKline, Merck, Merck Serono, Novartis, NovoNordisk, Pfizer, and Sanofi-Aventis, consulting fees from Amylin,Eli Lilly, GlaxoSmithKline, Merck, and Novartis, and lecturefees from Astella, Bayer, GlaxoSmithKline, King Pharmaceuticals,Eli Lilly, Merck, Merck Serono, Novo Nordisk, Takeda, and Sanofi-Aventis,and owning shares in Glyme Valley Technology, Glyox, and Oxtech;Dr. Paul, receiving consulting fees from Amylin; Dr. Bethel,receiving grant support from Novartis and Sanofi-Aventis andlecture fees from Merck and Sanofi-Aventis; Dr. Matthews, receivinglecture and advisory fees from Novo Nordisk, GlaxoSmithKline,Servier, Merck, Novartis, Novo Nordisk, Eli Lilly, Takeda, andRoche and owning shares in OSI Pharmaceuticals and ParticleTherapeutics; and Dr. Neil, receiving consulting fees from Merck,Pfizer, Schering-Plough, and Solvay Healthcare. The Oxford Centrefor Diabetes, Endocrinology and Metabolism (OCDEM) has a Partnershipfor the Foundation of OCDEM, with Novo Nordisk, Takeda and Servier.No other potential conflict of interest relevant to this articlewas reported.